{
    "organizations": [],
    "uuid": "0e4eccce865ae0188fa22f46b4b6e743c7b0cdc1",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-astrazeneca-updates-on-overall-sur/brief-astrazeneca-updates-on-overall-survival-data-for-lynparza-presented-at-aacr-idUSFWN1RT03Q",
    "ord_in_thread": 0,
    "title": "BRIEF-AstraZeneca Updates On Overall Survival Data For Lynparza Presented At AACR",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "April 16 (Reuters) - AstraZeneca PLC:\n* UPDATED OVERALL SURVIVAL DATA FOR LYNPARZA IN BRCA-MUTATED HER2-NEGATIVE METASTATIC BREAST CANCER PRESENTED AT AACR\n* LYNPARZA TRIAL MET ITS PRIMARY ENDPOINT OF PROGRESSION-FREE SURVIVAL\n* RESULTS AT AACR INCLUDE UPDATED FINDINGS FROM SECONDARY ENDPOINT OF OVERALL SURVIVAL Source text for Eikon: Further company coverage:\n ",
    "published": "2018-04-16T14:17:00.000+03:00",
    "crawled": "2018-04-17T12:09:51.062+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "april",
        "reuters",
        "astrazeneca",
        "plc",
        "updated",
        "overall",
        "survival",
        "data",
        "lynparza",
        "metastatic",
        "breast",
        "cancer",
        "presented",
        "aacr",
        "lynparza",
        "trial",
        "met",
        "primary",
        "endpoint",
        "survival",
        "result",
        "aacr",
        "include",
        "updated",
        "finding",
        "secondary",
        "endpoint",
        "overall",
        "survival",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}